Last viewed:
abcl
Prices are updated after-hours
ABCL
|
$3.82
-2.3%
620K
|
(0.0% 1d)
(-14.4% 1m)
(-43.1% 1y)
(0.0% 2d)
(0.0% 3d)
(-3.1% 7d)
(-6.4%
volume)
Earnings Calendar: 2024-02-20
Market Cap: $ 1,118,427,821
https://www.abcellera.com
Sec
Filling
|
Patents
| 206 employees
(CA) AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development.
drug discovery
education
antibody
add to watch list
Paper trade
email alert is off
Press-releases
AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024
Published: 2024-04-03
(Crawled : 23:00)
- biospace.com/
ABCL
|
$3.82
-2.3%
620K
|
| -6.25%
| O: -0.46%
H: 3.14%
C: 1.86%
first
report
financial
results
AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024
Published: 2024-03-19
(Crawled : 21:00)
- biospace.com/
ABCL
|
$3.82
-2.3%
620K
|
| -11.76%
| O: -1.96%
H: 0.0%
C: 0.0%
conference
AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions
Published: 2024-03-11
(Crawled : 17:00)
- biospace.com/
ABCL
|
$3.82
-2.3%
620K
|
| -15.09%
| O: 5.03%
H: 0.0%
C: 0.0%
BIIB
|
$193.75
1.7%
1M
|
Health Technology
| -12.58%
| O: 0.03%
H: 3.1%
C: 3.03%
neurological
AbCellera to Present at Upcoming Investor Conferences in March 2024
Published: 2024-02-23
(Crawled : 08:00)
- biospace.com/
ABCL
|
$3.82
-2.3%
620K
|
| -18.43%
| O: -1.21%
H: 0.0%
C: 0.0%
AbCellera Reports Full Year 2023 Business Results
Published: 2024-02-20
(Crawled : 23:00)
- biospace.com/
ABCL
|
$3.82
-2.3%
620K
|
| -24.16%
| O: 1.12%
H: 0.93%
C: -1.67%
business
year
results
AbCellera to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024
Published: 2023-12-20
(Crawled : 00:00)
- biospace.com/
ABCL
|
$3.82
-2.3%
620K
|
| -28.7%
| O: -1.94%
H: 0.0%
C: 0.0%
conference
AbCellera Presents New Data on Two T-Cell Engager Programs at SITC 2023
Published: 2023-11-03
(Crawled : 17:00)
- biospace.com/
ABCL
|
$3.82
-2.3%
620K
|
| -3.8%
| O: -6.18%
H: 0.0%
C: 0.0%
t-cell
AbCellera Reports Q3 2023 Business Results
Published: 2023-11-02
(Crawled : 00:00)
- biospace.com/
ABCL
|
$3.82
-2.3%
620K
|
| -1.94%
| O: 1.94%
H: 0.0%
C: 0.0%
business
results
Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology
Published: 2023-11-01
(Crawled : 20:00)
- globenewswire.com
ABCL
|
$3.82
-2.3%
620K
|
| -1.94%
| O: 1.94%
H: 0.0%
C: 0.0%
PRLD
|
$3.685
7.12%
42K
|
Health Technology
| 124.73%
| O: -6.45%
H: 29.31%
C: 27.01%
partnership
drug
antibody
therapeutics
AbCellera to Present at the Jefferies London Healthcare Conference on November 14, 2023
Published: 2023-10-31
(Crawled : 23:00)
- biospace.com/
ABCL
|
$3.82
-2.3%
620K
|
| 0.25%
| O: 0.87%
H: 0.0%
C: 0.0%
conference
See all
Last 15 days Sec forms
File Id
Form
Published Date
Transaction Date
Direction
Code
Amount Transacted
Owned Amount
0001703057-24-000008
4
2024-01-16
2024-01-14
Buy
A
770416
3913105
0001703057-24-000006
4
2024-01-16
2024-01-14
Buy
A
616333
3274714